UA90503U - Method for treating chronic heart failure - Google Patents

Method for treating chronic heart failure

Info

Publication number
UA90503U
UA90503U UAU201400351U UAU201400351U UA90503U UA 90503 U UA90503 U UA 90503U UA U201400351 U UAU201400351 U UA U201400351U UA U201400351 U UAU201400351 U UA U201400351U UA 90503 U UA90503 U UA 90503U
Authority
UA
Ukraine
Prior art keywords
rate
heart failure
chronic heart
beta
dose
Prior art date
Application number
UAU201400351U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Микола Тихонович Ватутін
Анна Миколаївна Шевельок
Олена Костянтинівна Нікіфорова
Ганна Володимирівна Кравченко
Original Assignee
Микола Тихонович Ватутін
Анна Миколаївна Шевельок
Олена Костянтинівна Нікіфорова
Ганна Володимирівна Кравченко
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микола Тихонович Ватутін, Анна Миколаївна Шевельок, Олена Костянтинівна Нікіфорова, Ганна Володимирівна Кравченко filed Critical Микола Тихонович Ватутін
Priority to UAU201400351U priority Critical patent/UA90503U/en
Publication of UA90503U publication Critical patent/UA90503U/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for treating the chronic heart failure comprises the medicamentous therapy with angiotensin-converting enzyme inhibitors, beta-adrenoblockers, aldosteron antagonists, the loop diuretics, digoxin, statins, antiaggregants. The breathing exercises also are used. The yoga breathing is provided, 8 cycles four times a day with respiratory rate of 8-10 breathings per minute. The loss of fluid is controlled. When the rate of fluid loss increases, the dose of the loop diuretic is decreased (approximately by 25 % or 20-40 mg/day expressed in terms of Furosemid) as well as the duration of parenteral administration (3-4 days less on the average). The heart rate is measured, and when the targeted rate is achieved, the dose of beta-adrenoblocker decreases approximately by 30 %.
UAU201400351U 2014-01-16 2014-01-16 Method for treating chronic heart failure UA90503U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201400351U UA90503U (en) 2014-01-16 2014-01-16 Method for treating chronic heart failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201400351U UA90503U (en) 2014-01-16 2014-01-16 Method for treating chronic heart failure

Publications (1)

Publication Number Publication Date
UA90503U true UA90503U (en) 2014-05-26

Family

ID=56268260

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201400351U UA90503U (en) 2014-01-16 2014-01-16 Method for treating chronic heart failure

Country Status (1)

Country Link
UA (1) UA90503U (en)

Similar Documents

Publication Publication Date Title
MX2021004821A (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy.
MX2023000320A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion.
MX2022006358A (en) Combined respiratory muscle training and oscillating positive expiratory pressure device.
MX2022015499A (en) Methods of treating crohn's disease and ulcerative colitis.
WO2013090118A3 (en) Heart rate variability and heart rate variation
SG10201908380TA (en) Treatment of fibrosis
WO2015017609A3 (en) Systems and methods for drug delivery, treatment, and monitoring
MY202377A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
MX2022015115A (en) Methods of treating heart failure with cardiac sarcomere activators.
BR112017026061A2 (en) compound, use of a compound, and method of treating a viral infection
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
MX2016011333A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.
MY176219A (en) Combination therapy for cancer
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
WO2015174864A8 (en) Methods and apparatus for flow therapy
CA3010788A1 (en) Methods of administering vasopressors
MX2021014523A (en) Methods of treating cholangiocarcinoma.
PH12020500374A1 (en) Treatment regimens
UA90503U (en) Method for treating chronic heart failure
SG11201808253YA (en) Marker for predicting treatment response to anti-cancer agent in solid cancer patients
WO2015017218A3 (en) Titration for medical infusion devices and systems
MX2020013385A (en) Methods of modulating tetrabenazine metabolites plasma levels using bupropion.
IL283422A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
UA98492U (en) A method of treating transient ischemic attack cardioembolic genesis
UA116484U (en) METHOD OF TREATMENT OF HYPERTENSION WITH METABOLIC SYNDROME